Portal de Periódicos da CAPES

Immune and gene therapy for melanoma, and the immunobiology of melanoma

1999; Wiley; Volume: 38; Issue: 7 Linguagem: Inglês

10.1046/j.1365-4362.1999.00746.x

1365-4632

Kathleen J. Smith, COL, MC. Usa, Henry G. Skelton,

T-cell and B-cell Immunology

International Journal of DermatologyVolume 38, Issue 7 p. 490-508 Immune and gene therapy for melanoma, and the immunobiology of melanoma Kathleen J. Smith, Kathleen J. Smith The Department of Dermatology, National Naval Medical Center, Bethesda, Maryland, and Laboratory Corporation of America, Burlington, CaliforniaSearch for more papers by this author. COL, . COL The Department of Dermatology, National Naval Medical Center, Bethesda, Maryland, and Laboratory Corporation of America, Burlington, CaliforniaSearch for more papers by this authorMC. USA, MC. USA The Department of Dermatology, National Naval Medical Center, Bethesda, Maryland, and Laboratory Corporation of America, Burlington, CaliforniaSearch for more papers by this authorHenry Skelton MD, Henry Skelton MD The Department of Dermatology, National Naval Medical Center, Bethesda, Maryland, and Laboratory Corporation of America, Burlington, CaliforniaSearch for more papers by this author Kathleen J. Smith, Kathleen J. Smith The Department of Dermatology, National Naval Medical Center, Bethesda, Maryland, and Laboratory Corporation of America, Burlington, CaliforniaSearch for more papers by this author. COL, . COL The Department of Dermatology, National Naval Medical Center, Bethesda, Maryland, and Laboratory Corporation of America, Burlington, CaliforniaSearch for more papers by this authorMC. USA, MC. USA The Department of Dermatology, National Naval Medical Center, Bethesda, Maryland, and Laboratory Corporation of America, Burlington, CaliforniaSearch for more papers by this authorHenry Skelton MD, Henry Skelton MD The Department of Dermatology, National Naval Medical Center, Bethesda, Maryland, and Laboratory Corporation of America, Burlington, CaliforniaSearch for more papers by this author First published: 25 December 2001 https://doi.org/10.1046/j.1365-4362.1999.00746.xCitations: 6 Kathleen J. Smith, col, mc usa, Department of Dermatology, National Naval Medical Center, Bethesda, MD 20089–5600 The opinions or assertions herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army, the Department of the Navy, or the Department of Defense Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Mackie, RM. Current epidemiology of malignant melanoma. In: M. Maio eds. Immunology of Human Melanoma. Amsterdam. IOS Press. , 1996: 11 15. 2 Rigel, D. Malignant melanoma: perspectives on incidence and its effects on awareness, diagnosis and treatment. CA Cancer J Clin.; 46 :195 198., 1996. 3 Parker, SL, Troy, T, Bolden, S, Wings, PA. Cancer statistics. 1997 CA Cancer J Clin 1997; 47, 5 27. 4 Garbe, C & Orfanos, CE. Epidemiology of malignant melanoma in central Europe: risk factors and prognostic predictors. Results of central malignant melanoma registry of the German Dermatologic Society. Pigment Cell Res 1992; 2, 285S 294S. 5 MacKie, RM, Hunter, JA, Aitchison, TC et al. Cutaneous malignant melanoma. Scotland 197889 The Scottish Melanoma Group. Lancet 1992; 339, 971 975. 6 Garbe, CC, Buttner, P, Bertz, J et al. Primary cutaneous melanoma: identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 1995; 75, 2484 2491. 7 Tucker, MA, Halpern, A, Holly, EA et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997; 14, 1439 1444. 8 Wingo, PA, Ries, LA, Rosenberg, HM et al. Cancer incidence and mortality. 1973–95: a report card for the U.S. Cancer 1998; 82, 1197 1201. 9 Armstrong, B. Epidemiology of malignant melanoma: intermittent or total accumulated exposure to the sun. J Dermatol Surg Oncol 1988; 14, 835 849. 10 Platz, A, Hansson, J, Ringborg, U. Screening of germline mutation in the CDK4, CDKN2C, and T53 genes in familial melanoma: a clinic-based population study. Int J Can 1998; 25, 13 15. 11 Kamb, A. Human melanoma genetics. J Invest Dermatol Symp Proc 1996; 1, 177 182. 12 Holman, CDI, Armstrong, BK, Heenan, PI. Relationship of cutaneous malignant melanoma to individual sun-light exposure habits. J Natl Cancer Inst 1986; 76, 403 414. 13 Atillasoy, ES, Seykora, JT, Soballe, PW et al. UVB induces atypical melanocytic lesions and melanoma in human skin. Am J Pathol 1998; 152, 1179 1186. 14 Ley, RD & Reeve, VE. Chemoprevention of ultraviolet radiation induced skin cancer. Environ Health Perspect 1997; 105 (Suppl. 4), 981 984. 15 Fork, HE, Wagner, RF, Wagner, KD. The Texas peer education sun awareness project for children: primary prevention of malignant melanoma and nonmelanocytic skin cancers. Cutis 1992; 50, 363 364. 16 MacKie, RM & Hole, D. Audit of public education campaign to encourage earlier detection of malignant melanoma. Br Med J 1992; 304, 1012 1015. 17 Demierre, M-F & Koh, HK. Adjuvant therapy for cutaneous malignant melanoma. J Am Acad Dermatol 1997; 36, 747 764. 18 Buzzell, RA & Zitelli, JA. Favorable prognosis factors in recurrent and metastatic melanoma. J Am Acad Dermatol 1996; 34, 798 803. 19 Day, CL, Jr, Sober, AJ, Lew, RA et al. Malignant melanoma patients with positive nodes and relatively good prognoses: microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional nodes. Cancer 1981; 47, 955 962. 20 Mastrangelo, MJ, Maguire, HC, Lattime, EC et al. Active specific immunotherapy with autologous whole tumor cell-based vaccines. In: M. Maio eds. Immunology of Human Melanoma. IOS Press. , 1996: 209 216. 21 Boon, T, Coulie, PG, Van den Eynde, B. Tumor antigens recognized by T cells. Immunol Today 1997; 18, 267 268. 22 Storkus, W & Lotze, M. Biology of tumor antigens: tumor antigens recognized by immune cells. In: V DeVita S Hellman S. Rosenberg eds. Biologic Therapy of Cancer, 2nd edn. Philadelphia: J.B. Lippincott. , 1995: 64 77. 23 Anichini, A, Mortarini, R, Mascalli, C et al. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate the HLA-A2.1 restricted immune repertoire to melanoma. J Immunol. in press, in press. 24 De Smet, C, Lurquin, C, Van Der Bruggen, P et al. Sequences and expression pattern of the human MAGE2 gene. Immunogenetics 1994; 39, 121 129. 25 Ball, P, Wildmann, C, Sensi, ML et al. BAGE. a new encoding of an antigen recognizing human melanoma by cytotoxic T lymphocytes. Immunity 1995; 2, 167 175. 26 Wang, RF, Robbins, PF, Kawatawi, Y et al. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 1995; 181, 799 804. 27 Wolfel, T, Van Pelt, A, Brichard, V et al. Two tyrosinase nonapeptides recognized on HLA-A2 restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180, 347 352. 28 Salgaller, ML, Marincola, FM, Cormier, JN, Rosenberg, SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996; 56, 4749 4757. 29 Wolfel, T, Hauer, M, Schneider, J et al. A p16INK4a insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269, 1281 1284. 30 Parmiami, G. Immunobiology of melanoma. In: M. Maio eds. Immunology of Human Melanoma. IOS Press. , 1996: 1 10. 31 Travesari, C & Coulie, PG. Human tumor-assciated antigens recognized by cytolyic T lymphocytes. In: M. Maio eds. Immunology of Human Melanoma. IOS Press. , 1996: 127 138. 32 Jager, E, Chen, IT, Drijfhout, K et al. Antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen HLA-A2 binding peptide epitopes. J Exp Med 1998; 19, 265 270. 33 Kirkin, AF, Dzhandzhugazyan, K, Zeuthen, J. Melanoma associated antigens recognized by cytotoxic T lymphocytes. APMIS 1998; 106, 665 679. 34 Ikeda, H, Lette, B, Lehmann, F et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expression of an NK inhibitory receptor. Immunity 1997; 6, 199 208. 35 Rivoltini, L. Functional characterization of T cell activity toward the melanoma associated antigen MART-1/Melan A. In: M. Maio eds. Immunology of Human Melanoma. IOS Press. , 1996: 145 151. 36 Rosenberg, SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997; 18, 175 182. 37 Rosenberg, SA, Yang, JC, Schwartsentruber, DJ et al. Immunologic and therapeutic evaluation of synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4, 321 327. 38 Coggin, JH, Baroum, AL, Rohrer, JW. Tumors express both unique TSTA and crossprotective 44kDa oncofetal antigen. Immunol Today 1998; 19, 405 408. 39 Olhoffer, IH & Bolognia, J. What’s new in the treatment of cutaneous melanoma? Semin Cut Med Surg 1998; 2, 96 107. 40 Chen, L. Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol Today 1998; 19, 27 30. 41 Hirohashi, S. Inactivation of the E-cadherin mediated cell adhesion system in human cancer. Am J Pathol 1998; 153, 333 339. 42 Ikeda, H, Lethe, B, Lehamann, F et al. Characterization of an antibody recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997; 6, 199 208. 43 Hickon, DJ, Kageshita, T, Dellaratta, DV et al. Defects in HLA class I antigen presentation machinery in melanoma cells. In: M. Maio eds. Immunology of Human Melanoma. IOS Press. , 1996: 95 111. 44 Wang, Z, Marqulies, L, Hicklen, DJ, Ferrone, S. Molecular and functional phenotypes of human melanoma cells with abnormalities in HLA class I antigen expression. Tissue Antigens 1996; 47, 382 390. 45 Wright, KL, White, LC, Kelly, A et al. Coordinate regulation of human TAP1 and LMP2 genes from a shared bidirectional promoter. J Exp Med 1995; 181, 1459 1471. 46 Higgins, CF. Introduction. the ABC transporter channel superfamily: an overview. Semin Cell Biol 1994; 4, 1 5. 47 Akiyama, K, Yokota, K, Kagawa, S et al. cDNA cloning and interferon-γ down regulation of proteasomal subunits X and Y. Science 1994; 265, 1231 1234. 48 Shamrock, CEM, Kaminski, E, Man, S. Limiting dilution analysis of human T cells: a useful clinical tool. Immunol Today 1990; 11, 281 286. 49 Oratz, R, Dugan, M, Roses, DF et al. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine. Cancer Res 1991; 51, 3643 3547. 50 Cascinelli, N, Rumke, P, MacKie, R et al. The significance of conversion of skin reactivity in efficacy of bacillus Calmette–Guérin adjuvant immunotherapy of stage II malignant melanoma. Cancer Immunol Immunother 1989; 28, 282 286. 51 Lipton, A, Harvey, HA, Balch, CM et al. Corynebacterium parvum versus bacillus-Calmette–Guérin adjuvant immunotherapy of stage II malignant melanoma. J Clin Oncol 1991; 9, 1151 1156. 52 Hersey, P, Coates, A, McCarthy, WH. Interim analysis of a randomized trial of immunotherapy with vaccina melanoma cell lysates (VMCL) following surgical removal of high risk melanoma. Proc Am Assoc Cancer Res 1996; 37, 489. 53 Wallack, MK, Sivanandham, M, Balch, CM et al. A phase II randomized double blind multi-institutional trial of vaccina melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995; 75, 34 42. 54 Mayordomo, JI, Zitvogel, L, Tjandrawan, T. Dendritic cells presenting tumor peptide epitopes stimulate effective antitumor CTL in vitro and in vivo. In: M. Maio eds. Immunology of Human Melanoma. IOS Press. , 1996: 153 163. 55 Nestle, FO, Aligagic, S, Gilliet, M et al. Vaccination of melanoma patients with peptide or tumor lysate pulsed dendritic cells. Nat Med 1998; 4, 328 332. 56 Sallusto, F & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179, 1109 1118. 57 Mayordomo, JI, Zorina, T, Storkus, WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic anti-tumor immunity. Nat Med 1995; 1, 1297 1302. 58 Zitvogel, L, Mayordomd, JI, Tjandrawan, T et al. Therapy of murine tumors with tumor peptide pulsed dendritic cells: dependence on T-Cells B7 costimulation and Th1-associated cytokines. J Exp Med 1995; 183, 87 97. 59 Mukerji, B, Chakraborty, NG, Hu, X, Sakamoto, T. Synthetic peptide pulsed autologous cultured antigen presenting cells as a melanoma vaccine. In: M. Maio eds. Immunology of Human Melanoma. IOS Press. , 1996: 201 208. 60 Galili, U & LaTemple, DC. Natural anti-Gal antibody as a universal augmentor of autologous tumor vaccine immunogenicity. Immunol Today 1997; 18, 281 285. 61 Cormier, JN & Marincola, FM. HLA antigens in melanoma. In: M. Maio eds. Immunology of Human Melanoma. IOS Press. , 1996: 81 93. 62 Chapman, PB. Differentiation antigens as targets for immunotherapy of melanoma. In: M. Maio eds. Immunology of Human Melanoma. IOS Press. , 1996: 195 200. 63 Roger, GS, Voseburg, W, Wazer, DE. New approaches to treating advanced melanoma: adjuvant treatment of high-risk primary melanoma and boron neutron capture therapy. Semin Cut Med Surg 1997; 16, 165 173. 64 Bohn, M, Moller, P, Grunewald, C, Czanelzki, BM. Interleukin 7 induces differentiation of lymphocyte activated killer cell activity against human melanoma cells, keratinocytes, and endothelial cells. J Invest Dermatol 1994; 102, 838 842. 65 Mingari, MC, Maggi, E, Cambaggi, A et al. Development in vitro of human CD4+ thymocytes into functionally mature Th2 cells. Exogenous IL-12 is required for priming of thymocytes to both Th1 cytokine and IL-10. Eur J Immunol 1995; 25, 2656 2660. 66 Van Elasa, A, Van Der Minne, C, Borghi, M et al. CTL recognition of an IL-2 producing human melanoma vaccine. In: M. Maio eds. Immunology of Human Melanoma. IOS Press. , 1996: 165 173. 67 Rao, JB, Chamberlain, RS, Bronte, V et al. Interleukin 12 is an effective adjuvant to recombinant vaccina virus based tumor vaccines. J Immunol 1996; 156, 3357 3365. 68 Qin, Z, Richter, G, Schuler, T et al. B cells inhibit induction of T-cell dependent tumor immunity. Nat Med 1998; 4, 627 630. 69 Luger, TA & Bohm, M. Melanoma-derived cytokines. In: M. Maio eds. Immunology of Human Melanoma. IOS Press. , 1996: 55 69. 70 Morelli, JG & Norris, DA. Influence of inflammatory mediators and cytokines on human melanocyte function. J Invest Dermatol 1993; 100, 191S 195S. 71 Shih, LM & Herlyn, M. Role of growth factors and their receptors in the development and progression of melanoma. J Invest Dermatol 1993; 100, 196S 203S. 72 Krasagakis, K, Garbe, C, Orfanos, CE. Cytokines in human melanoma cells: synthesis, autocrine stimulation and regulatory functions—an overview. Melanoma Res 1993; 3, 425 433. 73 Lu, C & Kerbel, RS. Cytokine growth features and the loss of negative growth control in progression of human cutaneous malignant melanoma. Curr Opin Oncol 1994; 6, 212 220. 74 Schadendorf, D, Miller, A, Algermission, B et al. IL-8 produced by human melanoma cells in vitro is an essential autocrine growth factor. J Immunol 1993; 151, 2667 2675. 75 Rodeck, U, Bossler, A, Graenen, V et al. Transforming growth factor beta production and responsiveness in normal melanocytes and melanoma cells. Cancer Res 1994; 54, 575 581. 76 Filmus, J & Kerbel, RS. Development of resistance mechanisms to the growth-inhibitory effects of transforming growth factor beta during tumor progression. Curr Opin Oncol 1993; 5, 123 129. 77 Armstrong, CA et al. Melanoma growth in vivo is inhibited by melanoma derived GM-CSF. Clin Res 1994; 80, 876. 78 Chen, Q, Danial, V, Maher, DW, Hersey, P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994; 56, 755 760. 79 Coleman, AB & Lugo, TG. Normal human melanocytes that express a bFGF transgene still require exogenous B FGF for growth in vitro. J Invest Dermatol 1998; 110, 793 799. 80 Golab, J, Stoklasa, T, Zagozdzon, R et al. Granulocyte-macrophage colony-stimulating factor potentiates antitumor activity of interleukin-12 in melanoma model in mice. Tumour Biol 1998; 19, 77 87. 81 Golab, J, Stoklosa, T, Zagozdzon, R et al. G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice. Ann Oncol 1998; 9, 63 69. 82 Dummer, W, Bastian, BC, Ernst, N et al. Interleukin 10 in melanoma patients is associated with advanced disease. Arch Dermatol Res 1995; 287, 347. 83 Belli, F, Mascheroni, L, Cascinelli, N. Potential role of interferon in the treatment of metastatic melanoma. In: M. Maio eds. Immunology of Human Melanoma. IOS Press. , 1996: 217 226. 84 Kirkwood, JM, Strawderman, MH, Ernstroff, MS et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanomas; the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14, 7 17. 85 Grob, JJ, Dreno, B, Delaunay, M et al. Results of the French multicenter trial on adjuvant therapy with interferon alfa-2a in resected primary melanoma (>1.5 mm). Proc Am Soc Clin Oncol 1996; 15, 437. 86 Creagan, ET, Dalton, RJ, Ahmann, DL et al. Randomized, surgical adjuvant clinical trials of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995; 13, 2776 2783. 87 Meyskens, FL, Kopecky, KJ, Taylor, CW et al. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group Study. J Natl Cancer Inst 1995; 87, 1710 1712. 88 Rusciani, L, Petraglia, S, Alotto, M et al. Postsurgical adjuvant therapy for melanoma: evaluation of a 3-year randomized trial with recombinant interferon-γ after 3 and 5 years of follow-up. Cancer 1997; 79, 2354 2360. 89 Parronchi, P, De Carli, M, Manetti, R et al. IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by the Th1 and Th2 human T cell clones. J Immunol 1992; 149, 2977 2983. 90 Finkelman, FD, Svetic, A, Gresser, I et al. Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice. J Exp Med 1991; 174, 1179 1188. 91 Gunzburg, WH & Salmons, B. Virus vector design in gene therapy. Mol Med Today 1995; 1, 410 417. 92 Stewart, WE II. The Interferon System. New York. Springer-Velag, 1981. 93 Nathan, CF, De Horowitz, CR, La Harpe, J et al. Administration of recombinant interferon-γ to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci USA 1985; 82, 8686 8690. 94 Herlyn, M, Guerry, D, Koprowski, H. Recombinant γ-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells. J Immunol 1985; 134, 4226 4230. 95 Houghton, AN, Thomson, TM, Gross, D et al. Surface antigens of melanoma and melanocytes: specificity of induction of Ia antigens by human γ-interferon. J Exp Med 1984; 160, 255 269. 96 Abdel-Wahab, Z, Weltz, C, Hester, D et al. A phase I clinical trial of immunotherapy with interferon-γ gene-modified autologous melanoma cells. 1997; 80, 401 412. 97 Zier, K, Gansbacher, B, Salvadori, S. Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol Today 1996; 17, 39 45. 98 Culver, KW, Vickers, TM, Lamsam, JL et al. Gene therapy for solid tumors. In: AML Lever P. Goodfellow eds. Gene Therapy. Glasgow: Bell and Brain.,, 1995: 192 204. 99 Treco, DA & Selden, RF. Non-viral gene theapy. Mol Med Today 1995; 1, 314 321. 100 Caruso, M. Gene therapy against cancer and HIV infection using the gene encoding herpes simplex virus thymidine kinase. Mol Med Today 1996; 2, 212 217. 101 Cavallo, F, Modesti, A, Musiani, P et al. Pre-clinical models of cytokine mediated gene therapy. In: M. Maio eds. Immunology of Human Melanoma. IOS Press. , 1996: 177 183. 102 Longo, DL. New clinical prospects. In: G Forni R Foa A Santoni L. Frati eds. Cytokine Induced Tumor Immunogenicity. London. Academic Press. ,, 1994: 469 474. 103 Vile, RG & Russell, SJ. Retroviruses as vectors. In: AML Lever P. Goodfellow eds. Gene Therapy. Glasgow: Bell and Brain.,, 1995: 12 30. 104 Melcher, A, Todryk, S, Hardwick, N et al. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 1998; 4, 581 587. 105 Funk, JO, Schiller, PI, Barrett, MT et al. p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma. J Cutan Pathol 1998; 25, 291 296. 106 Fuevo, J, Gomez-Manzano, C, Yung, WKA et al. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med 1998; 4, 685 690. 107 Rossi, JJ. Therapeutic antisense and ribozymes. In: AML Lever P. Goodfellow eds. Gene Therapy. Glasgow, Bell and Brain.,, 1995: 217 225. 108 Weatherall, DJ. Scope and limitations of gene therapy. In: AML Lever P. Goodfellow eds. Gene Therapy. Glasgow, Bell and Brain.,, 1995: 1 11. 109 Musiani, P, Allione, A, Lollini, PL et al. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. Lab Invest 1996; 74, 146 157. 110 Tige, H, Corr, M, Roman, M, Raz, E. Gene vaccination: plasmic DNA is more than just a blueprint. Immunol Today 1998; 19, 89 97. 111 Tuting, T, Storkus, WJ, Falo, LD. DNA immunization targeting the skin: molecular control of adaptive immunity. J Invest Dermatol 1998; 111, 183 188. 112 Fricker, J. Interleukin 7 on trial for melanoma treatment. Mol Med Today 1996; 2, 2. 113 Cayeux, S, Richter, G, Noffz, G et al. Influence of gene-modified (IL-7, IL-4 and B7) tumor cell vaccines on tumor antigen presentation. J Immunol 1997; 158, 2834 2841. 114 Bagshawe, KD. Antibody-directed enzyme prodrug therapy for cancer: its theoretical basis and application. Mol Med Today 1995; 1, 424 431. 115 Kerr, DE, Schreiber, GJ, Vrudhata, VM et al. Regressions and cures of melanoma xenografts following treatment with monclonal antibody β-lactamase conjugates in combination with anti-cancer prodrugs. Cancer Res 1995; 55, 3558 3568. 116 Mingari, MC, Moretta, A, Moretta, L. Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. Immunol Today 1998; 19, 153 156. 117 Brasoveanu, LI, Altomonte, M, Fonsatti, E et al. Role of protectin (CD59) as regulator of complement mediated lysis of melanoma cells: relevance in immunotherapy. In: M. Maio eds. Immunology of Human Melanoma. IOS Press. , 1996: 185 193. 118 Plantelli, M, Ranelletti, FO, Maggiano, N et al. Tamoxifen and Quercetin in melanoma cell growth. Role of type II estrogen binding sites. In: M. Maio eds. Immunology of Human Melanoma. IOS Press. , 1996: 47 54. 119 Vigh, Z, Literati, PN, Horvath, I et al. Bimoclomol: a nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects. 1997; 3, 1150 1154. 120 Ruegg, C, Yilmaz, A, Bieler, G et al. Evidence for the involvement of endothelial cell integrin (V (3 in the disruption of the tumor vasculature induced by TNF and IFN-γ. Nat Med 1998; 4, 408 414. 121 Godellas, CV, Berman, CG, Lyman, G et al. The identification and mapping of melanoma regional nodal metastases: minimally invasive surgery for the diagnosis of nodal metastases. Ann Surg 1995; 61, 97 101. 122 Studt, T. Maturing combinatorial chemistry creates new technology base. Res Dev 1997; 39, 32 34. 123 Seliger, B, Maeurer, MJ, Ferrone, S. TAP off–tumors on. Immunol Today 1997; 18, 292 299. Citing Literature Volume38, Issue7July 1999Pages 490-508 ReferencesRelatedInformation